A STUDY ON LIVER FUNCTION TEST PROFILE OF 2ND LINE DRUGS IN MULTI DRUG RESISTANT (MDR) AND EXTENSIVELY DRUG RESISTANT (XDR) TUBERCULOSIS CASES REGISTERED UNDER DR-TB CENTRE IN A TERTIARY CARE HOSPITAL

Dr Rupam Kumar Ta, Dr. Pronoy Sen

Abstract


BACKGROUND: The emergence of drug resistant mycobacterium has become a signicant public
health problem creating an obstacle to effective Tuberculosis (TB) control. Freedom from TB is possible
with timely, regular, complete treatment, with assurance, prevention and management of side effects of antitubercular drugs.
Present study was conducted to evaluate common and rare adverse drug reactions (ADR) of CAT IV and CAT V to analyse
demographic, radiological and bacteriological prole and treatment outcome in MDR &XDR patients.
Aims and Objectives- To evaluate the common and rare adverse drug reactions of intensive phase treatment of Multi Drug
Resistant Tuberculosis (MDR) and Extensively Drug Resistant Tuberculosis (XDR) as per WHO-UMC Causality Assessment
Scale.
METHODS: 76 patients of MDR and XDR Tuberculosis were admitted in DR-TB (Drug Resistant TB) centre, Burdwan Medical
College and Hospital and the adverse drug reaction prole of 2nd line drugs were analysed during the intensive phase for a
year after fullling the inclusion and exclusion criteria. Treatment was given as per guidelines by Revised National TB Control
Program PMDT (Programmatic management of drug-resistant TB).
RESULTS: Adverse drug reactions on GI system were nausea 73 patients (96.10%), vomiting 70 (92.10%), acidity 41 (53.9%), and
sulphurous belching and hepatitis 1 (1.31%) each.
CONCLUSIONS: The reactions were common in rst 60 days of the regimen and in patients with BMI ≤18. Hence vigilant
monitoring is required for these types of patients during the initial period and sputum smear and culture conversion is very well
correlated with clinical and radiological improvement.


Full Text:

PDF

References


Report WHO/HTM/TB/2006.375 (World Health Organization, Geneva, 2006),Centers for Disease Control and Prevention. Revised definition of extensively drug-resistant tuberculosis. MMWR 2006; 55:1176)

World Health Organization. Multidrug and extensively drug-resistant TB(M/XDR-TB): 2014.

Mahadev B, Kumar P, Agarwal SP, Chauhan LS, Srikantaramu N. Surveillance of drug resistance to anti-tuberculosis drugs in districts of Hoogli in West Bengal and Mayurbhanj in Orissa. [Last cited on 2019 Dec 6]; Indian J Tuberc. 2005 52:5–10. Available from: http://www.imsear.li.mahidol.ac.th/handle/123456789/146942 .

Paramasivan CN, Venkataraman P, Chandrasekaran V, Bhat S, Narayanan PR. Surveillance of drug resistance in tuberculosis in two districts of South India. Int J Tuberc Lung Dis 2002: 6 (6); 479-84

Guidelines on Programmatic Management of Drug Resistant TB (PMDT) in India 2012 https://tbcindia.gov.in/WriteReadData/l892s/8320929355Guidelines%20for%20PMDT%20in%20India%20-%20May%202012.pdf

Patel S, Bhikhubhai N, Patel A, Shringarpure K, Mehta K, Shukla L, et al. Adverse Drug Reactions in Patients put on Multi Drug Resistant Tuberculosis (MDR-TB) Treatment in Seven Districts of Central Gujarat. Jour Young Pharmacists [Internet]. 2015:7(4); 425-31. [cited 2019 Dec 6] Available from: https://www.jyoungpharm.org/sites/default/files/10.5530jyp.2015.4s.3.pdf

Hire R, Kale AS, Dakhale GN, Gaikwad N. A prospective, observational study of adverse reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in central India. Mediterr J Hematol Infect Dis. 2014;6(1):e2014061.

Dela AI, Tank NKD, Singh AP, Piparva KG. Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study. Lung India. 2017 Dec;34(6):522–6.

Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, Tupasi TE, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis. 2004 Nov;8(11):1382–4.


Refbacks

  • There are currently no refbacks.